Literature DB >> 20858595

A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice.

Anne-Cécile Durieux1, Alban Vignaud, Bernard Prudhon, Mai Thao Viou, Maud Beuvin, Stéphane Vassilopoulos, Bodvaël Fraysse, Arnaud Ferry, Jeanne Lainé, Norma B Romero, Pascale Guicheney, Marc Bitoun.   

Abstract

Autosomal dominant centronuclear myopathy (AD-CNM) is due to mutations in the gene encoding dynamin 2 (DNM2) involved in endocytosis and intracellular membrane trafficking. To understand the pathomechanisms resulting from a DNM2 mutation, we generated a knock-in mouse model expressing the most frequent AD-CNM mutation (KI-Dnm2(R465W)). Heterozygous (HTZ) mice developed a myopathy showing a specific spatial and temporal muscle involvement. In the primarily and prominently affected tibialis anterior muscle, impairment of the contractile properties was evidenced at weaning and was progressively associated with atrophy and histopathological abnormalities mainly affecting mitochondria and reticular network. Expression of genes involved in ubiquitin-proteosome and autophagy pathways was up-regulated during DNM2-induced atrophy. In isolated muscle fibers from wild-type and HTZ mice, Dnm2 localized in regions of intense membrane trafficking (I-band and perinuclear region), emphasizing the pathophysiological hypothesis in which DNM2-dependent trafficking would be altered. In addition, HTZ fibers showed an increased calcium concentration as well as an intracellular Dnm2 and dysferlin accumulation. A similar dysferlin retention, never reported so far in congenital myopathies, was also demonstrated in biopsies from DNM2-CNM patients and can be considered as a new marker to orientate direct genetic testing. Homozygous (HMZ) mice died during the first hours of life. Impairment of clathrin-mediated endocytosis, demonstrated in HMZ embryonic fibroblasts, could be the cause of lethality. Overall, this first mouse model of DNM2-related myopathy shows the crucial role of DNM2 in muscle homeostasis and will be a precious tool to study DNM2 functions in muscle, pathomechanisms of DNM2-CNM and developing therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858595     DOI: 10.1093/hmg/ddq413

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  56 in total

1.  Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness.

Authors:  Belinda S Cowling; Anne Toussaint; Leonela Amoasii; Pascale Koebel; Arnaud Ferry; Laurianne Davignon; Ichizo Nishino; Jean-Louis Mandel; Jocelyn Laporte
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects.

Authors:  Diána Papp; Tibor Kovács; Viktor Billes; Máté Varga; Anna Tarnóci; László Hackler; László G Puskás; Hanna Liliom; Krisztián Tárnok; Katalin Schlett; Adrienn Borsy; Zsolt Pádár; Attila L Kovács; Krisztina Hegedűs; Gábor Juhász; Marcell Komlós; Attila Erdős; Balázs Gulyás; Tibor Vellai
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

3.  The intragenic microRNA miR199A1 in the dynamin 2 gene contributes to the pathology of X-linked centronuclear myopathy.

Authors:  Xin Chen; Yun-Qian Gao; Yan-Yan Zheng; Wei Wang; Pei Wang; Juan Liang; Wei Zhao; Tao Tao; Jie Sun; Lisha Wei; Yeqiong Li; Yuwei Zhou; Zhenji Gan; Xuena Zhang; Hua-Qun Chen; Min-Sheng Zhu
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

4.  A mutation associated with centronuclear myopathy enhances the size and stability of dynamin 2 complexes in cells.

Authors:  Nicholas G James; Michelle A Digman; Justin A Ross; Barbara Barylko; Lei Wang; Jinhui Li; Yan Chen; Joachim D Mueller; Enrico Gratton; Joseph P Albanesi; David M Jameson
Journal:  Biochim Biophys Acta       Date:  2013-09-07

5.  DNM2 mutations in Chinese Han patients with centronuclear myopathy.

Authors:  Pengfei Lin; Xinhong Liu; Dandan Zhao; Tingjun Dai; Huamin Wu; Yaoqin Gong; Chuanzhu Yan
Journal:  Neurol Sci       Date:  2016-02-23       Impact factor: 3.307

6.  Dynamin 2 the rescue for centronuclear myopathy.

Authors:  Alexis R Demonbreun; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

7.  Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.

Authors:  Belinda S Cowling; Thierry Chevremont; Ivana Prokic; Christine Kretz; Arnaud Ferry; Catherine Coirault; Olga Koutsopoulos; Vincent Laugel; Norma B Romero; Jocelyn Laporte
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

8.  Mice lacking microRNA 133a develop dynamin 2–dependent centronuclear myopathy.

Authors:  Ning Liu; Svetlana Bezprozvannaya; John M Shelton; Madlyn I Frisard; Matthew W Hulver; Ryan P McMillan; Yaru Wu; Kevin A Voelker; Robert W Grange; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

9.  Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome.

Authors:  Olga S Koutsopoulos; Christine Kretz; Claudia M Weller; Aurelien Roux; Halina Mojzisova; Johann Böhm; Catherine Koch; Anne Toussaint; Emilie Heckel; Daphne Stemkens; Simone A J Ter Horst; Christelle Thibault; Muriel Koch; Syed Q Mehdi; Emilia K Bijlsma; Jean-Louis Mandel; Julien Vermot; Jocelyn Laporte
Journal:  Eur J Hum Genet       Date:  2012-10-24       Impact factor: 4.246

10.  Bridging integrator 1 (Bin1) deficiency in zebrafish results in centronuclear myopathy.

Authors:  Laura L Smith; Vandana A Gupta; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2014-02-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.